Outcomes of patients treated with caplacizumab as initial treatment vs patients not treated with caplacizumab
| . | patients with iTTP treated with caplacizumab as initial treatment (n = 44) . | patients with iTTP not treated with caplacizumab (n = 78) . | P . |
|---|---|---|---|
| Clinical remission | 42/44 (95.5%) | 73/78 (93.6%) | .6501 |
| Exacerbation | 2/44 (4.5%) | 16/78 (20.5%) | .023 |
| Refractoriness∗ | 2/44 (4.5%) | 11/78 (14.1%) | .042 |
| Death | 2/44 (4.5%) | 6/78 (7.7%) | .567 |
| . | patients with iTTP treated with caplacizumab as initial treatment (n = 44) . | patients with iTTP not treated with caplacizumab (n = 78) . | P . |
|---|---|---|---|
| Clinical remission | 42/44 (95.5%) | 73/78 (93.6%) | .6501 |
| Exacerbation | 2/44 (4.5%) | 16/78 (20.5%) | .023 |
| Refractoriness∗ | 2/44 (4.5%) | 11/78 (14.1%) | .042 |
| Death | 2/44 (4.5%) | 6/78 (7.7%) | .567 |
The 2 patients who were refractory to treatment were those who died, although they were different from the other 2 who had an exacerbation.